Development of a decision analytic model to support decision making and risk communication about thrombolytic treatment Clinical decision-making, knowledge support systems, and theory

BMC Medical Informatics and Decision Making

Volumn 15, Issue 1, 2015, Pages

  McMeekin, Peter ^a,b   Flynn, Darren ^a   Ford, Gary A ^a   Rodgers, Helen ^a   Gray, Jo ^b   Thompson, Richard G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

Author keywords

Acute Cerebral Infarction; Clinical Decision Support; Emergency treatment of Stroke; Predictive Models; Thrombolysis

Indexed keywords

ADVERSE EFFECTS; AGED; BRAIN ISCHEMIA; COMPLICATION; DECISION SUPPORT SYSTEM; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MALE; MIDDLE AGED; REGISTER; STANDARDS; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; STROKE; THROMBOLYTIC THERAPY;

EID: 84947863426     PISSN: None     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/s12911-015-0213-z     Document Type: Article

References (25)

1. Murtagh MJ, Watson DLB, Jenkings KN, Lie MLS, Mackintosh JE, Ford GA, et al. Situationally-Sensitive Knowledge Translation and Relational Decision Making in Hyperacute Stroke: A Qualitative Study. PLoS One. 2012;7:e37066.
2. Lecouturier J, Murtagh MJ, Thomson RG, Ford GA, White M, Eccles M, et al. Response to symptoms of stroke in the UK: a systematic review. BMC Health Serv Res. 2010;10:157.
3. Dirks M, Niessen LW, Koudstaal PJ, Franke CL, van Oostenbrugge RJ, Dippel DW, et al. Delphi panel on indications and contraindications for intravenous thrombolysis in acute ischaemic stroke. Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study. J Neurol Neurosurg Psychiatry. 2007;78:685-9.
4. Kwan J, Hand P, Sandercock P. A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing. 2004;33:116-21.
5. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational Study. Lancet. 2007;369:275-82.
6. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004;35:e27-9.
7. Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. Stroke. 2011;42:2257-62.
8. Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009;40:1710-20.
9. Kongnakorn T, Ward A, Roberts CS, O'Brien JA, Proskorovsky I, Caro JJ. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health. 2009;12:880-7.
10. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial apply?". Lancet. 2005;365:82-93.
11. Hunink MM, Weinstein MC, Wittenberg E, Drummond MF, Pliskin JS, Wong JB, et al. Decision making in health and medicine: integrating evidence and values, 2nd ed. 2014. Cambridge, UK: Cambridge University Press,.
12. Kent D, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The Stroke-Thrombolytic Predictive Instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006;37:2957-62.
13. McMeekin P, Flynn D, Ford GA, Rodgers H, Thomson RG. Validating the Stroke-Thrombolytic Predictive Instrument in a Population in the United Kingdom. Stroke. 2012;43:3378-81.
14. Uyttenboogaart M, Stewart RE, Vroomen PC, De KJ, Luijckx GJ. Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke. 2005;36:1984-7.
15. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, et al. Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials Safe Implementation of Thrombolysis in Stroke-Monitoring STudy (SITS-MOST). Stroke. 2008;39:3316-22.
16. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-82. doi: 10.1016/S0140-6736(07)60149-4.
17. Ali M, Bath P, Brady M, Davis S, Diener H-C, Donnan G, et al. Development, Expansion and Use of a Stroke Clinical Trials Resource for Novel Exploratory Analyses. Int J Stroke. 2012;7:133-8.
18. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
19. Hosmer DW, Lemeshow S. Applied Logistic Regression (2nd Edition). New York: John Wiley & Sons; 2000.
20. Cucchiara B, Kasner SE, Tanne D, Levine SR, Demchuk A, Messe SR, Sansing L et al. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) 1 and SAINT II trials. Stroke. 2000;40: 3067-72
21. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, et al. Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score. Stroke. 2012;43:1524-31.
22. Thompson DD, Murray GD, Sudlow CLM, Dennis M, Whiteley WN. Comparison of Statistical and Clinical Predictions of Functional Outcome after Ischemic Stroke. PLoS One. 2014;9(10):e110189. doi: 10.1371/journal.pone.0110189.
23. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E et al.Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014. Volume 384, Issue 9958, 1929-1935
24. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379:2364-72.
25. Flynn D, Nesbitt D, Ford GA, McMeekin P, Rodgers H, Price C, et al. Development of a computerised decision aid for thrombolysis in acute stroke care. BMC Med Inform Decis Mak. 2015;15:6.